9.325
4.02%
0.365
アフターアワーズ:
9.81
0.485
+5.20%
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals CMO sells shares worth $74,765 - Investing.com India
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 Shares - MarketBeat
Kalvista Pharmaceuticals CMO sells shares worth $74,765 By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 - Investing.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by First Turn Management LLC - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Insight into TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of KalVista Pharmaceuticals Inc Shares - GuruFocus.com
Suvretta Capital Management, LLC Increases Stake in KalVista Pha - GuruFocus.com
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuti - GuruFocus.com
Capital World Investors Expands Stake in KalVista Pharmaceuticals - GuruFocus.com
Objective long/short (KALV) Report - Stock Traders Daily
KalVista Pharma (KALV) to Present at Stifel and Jefferies Healthcare Conferences | KALV Stock News - StockTitan
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Leerink Partnrs Has Bullish Estimate for KALV Q3 Earnings - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance
KalVista prices $55M stock offering - MSN
Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com
KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com
U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpHere's Why - MarketBeat
KalVista sets pricing for $60 million stock offering - Investing.com
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart
Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Yahoo Finance
KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com
Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
(KALV) Long Term Investment Analysis - Stock Traders Daily
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa
sebetralstat shows promise in phase 3 HAE trial - Investing.com India
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian
Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR
(KALV) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat
Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR
(KALV) Technical Data - Stock Traders Daily
Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat
Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa
Kalvista shares hold Buy rating, price target on HAE study - Investing.com
大文字化:
|
ボリューム (24 時間):